Activation of p70 S6 kinase and erk-encoded mitogen-activated protein kinases is resistant to high cyclic nucleotide levels in Swiss 3T3 fibroblasts.
Treatment of Swiss mouse 3T3 fibroblasts with certain cyclic nucleotide phosphodiesterase inhibitors (theophylline, SQ 20,006, and MY-5445) prevents the activation of the M(r) 70,000 S6 kinase (p70S6k) induced by a variety of external stimuli. Concentrations giving half-maximal inhibition were 800, 50, and 25 microM, respectively. Western blot analysis and immunocomplex kinase assays showed that these compounds inhibit the phosphorylation and activation of p70S6k without affecting the erk-encoded mitogen-activated protein (MAP) kinases or the rsk-encoded S6 kinase (p90rsk). A distinct collection of cAMP and cGMP agonists and analogues did not suppress p70S6k activation, indicating that 1) high intracellular cyclic nucleotide concentrations do not antagonize the p70S6k pathway and 2) phosphodiesterase inhibitors block p70S6k activation by a mechanism that is independent of cAMP or cGMP production. The effect of theophylline and SQ 20,006, but not MY-5445, on p70S6k signaling may be due in part to the inhibition of a phosphatidylinositol 3-kinase that acts upstream of p70S6k. Finally, in contrast to many other cell types, cAMP and cGMP were also found to have no inhibitory effect on the MAP kinase/p90rsk signaling pathway in Swiss 3T3 fibroblasts.
Petritsch
C
C
Institute of Molecular Pathology, Vienna, Austria.
Woscholski
R
R
Edelmann
H M
HM
Ballou
L M
LM
D016475:3T3 Cells; D015124:8-Bromo Cyclic Adenosine Monophosphate / Q000494:pharmacology; D000527:Alprostadil / Q000494:pharmacology; D000818:Animals; D017871:Calcium-Calmodulin-Dependent Protein Kinases / Q000096:biosynthesis / Q000378:metabolism*; D000242:Cyclic AMP / Q000378:metabolism*; D006152:Cyclic GMP / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D004789:Enzyme Activation; D004815:Epidermal Growth Factor / Q000494:pharmacology; D007700:Kinetics; D051379:Mice; D020928:Mitogen-Activated Protein Kinases / Q000378:metabolism*; D009419:Nerve Tissue Proteins / Q000096:biosynthesis / Q000378:metabolism*; D009539:Nicotinic Acids / Q000494:pharmacology; D019869:Phosphatidylinositol 3-Kinases; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology; D017853:Phosphotransferases (Alcohol Group Acceptor) / Q000037:antagonists & inhibitors; D010793:Phthalazines / Q000494:pharmacology; D017346:Protein Serine-Threonine Kinases / Q000378:metabolism*; D019893:Ribosomal Protein S6 Kinases; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology; D013806:Theophylline / Q000494:pharmacology
D015124:8-Bromo Cyclic Adenosine Monophosphate; D000527:Alprostadil; D017871:Calcium-Calmodulin-Dependent Protein Kinases; D000242:Cyclic AMP; D006152:Cyclic GMP; D004815:Epidermal Growth Factor; D020928:Mitogen-Activated Protein Kinases; D009419:Nerve Tissue Proteins; D009539:Nicotinic Acids; D019869:Phosphatidylinositol 3-Kinases; D010726:Phosphodiesterase Inhibitors; D017853:Phosphotransferases (Alcohol Group Acceptor); D010793:Phthalazines; D017346:Protein Serine-Threonine Kinases; D019893:Ribosomal Protein S6 Kinases; D013806:Theophylline; C011610:SQ 20006; C052490:MY 5445